Patent SG-11201907769X-A (SG)
Title: Cd80 variant immunomodulatory proteins and uses thereof
Inventor: SWANSON RYAN
IPC: C07K14/705
Filed: 2018-03-13
Abstract: WO 18/ 17 00 26 A3 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 20 September 2018 (20.09.2018) WIP0 I PCT ill~~~~~~~~ 011101010VIIIOH olo olo monliolom (10) International Publication Number WO 2018/170026 A3 (51) International Patent Classification: C07K 14/705 (2006.01) (21) International Application Number: PCT/US2018/022270 (22) International Filing Date: 13 March 2018 (13.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/472,554 16 March 2017 (16.03.2017) US 62/472,558 16 March 2017 (16.03.2017) US 62/472,569 16 March 2017 (16.03.2017) US 62/472,572 16 March 2017 (16.03.2017) US 62/472,573 17 March 2017 (17.03.2017) US 62/475,204 22 March 2017 (22.03.2017) US 62/537,939 27 July 2017 (27.07.2017) US 62/574,165 18 October 2017 (18.10.2017) US 62/582,266 06 November 2017 (06.11.2017) US (71) Applicant: ALPINE IMMUNE SCIENCES, INC. [US/US]; 201 Elliott Avenue West, Suite 230, Seattle, Washington 98119 (US). (72) Inventors: SWANSON, Ryan; 201 Elliott Avenue West, Suite 230, Seattle, Washington 98119 (US). KORNACK- ER, Michael; 201 Elliott Avenue West, Suite 230, Seat- tle, Washington 98119 (US). MAURER, Mark F.; 201 El- liott Avenue West, Suite 230, Seattle, Washington 98119 (US). ARDOUREL, Dan; 201 Elliott Avenue West, Suite 230, Seattle, Washington 98119 (US). DEMONTE, Daniel William; 201 Elliott Avenue West, Suite 230, Seattle, Washington 98119 (US). KUIJPER, Joseph L.; 201 Elliott Avenue West, Suite 230, Seattle, Washington 98119 (US). (74) Agent: AIKEN, Charity et al.; 12531 High Bluff Drive, Suite 100, San Diego, California 92130-2040 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (54) Title: CD80 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF FIG. 3A Ci 4 (57) : Provided herein are variant CD80 polypeptides, immunomodulatory proteins comprising variant CD80 polypeptides, and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological and oncological conditions. Compositions and methods for making and using such proteins are provided. [Continued on next page] WO 2018/170026 A3 IMEDIMO DOI 01011MENOMMENIMMEO111EEN KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) of inventorship (Rule 4.17(iv)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) (88) Date of publication of the international search report: 18 October 2018 (18.10.2018)